Concept Solid Tumors

HEREDITARY CANCERS

Hereditary cancers account for ~5% of all malignancies and occur because of an inherited deleterious gene alteration from one of the parents. People carrying such alteration have a high risk of developing cancer at an early age, as well as developing multiple synchronous or metachronous cancers. Genetic screening of high-risk populations, such as individuals with a family history of cancer, is important in identifying cancer-related germline genetic variants and the chance of developing cancer in your lifetime, prompting early discovery of cancer lesions and improving patient survival. It also reveals genetic mutations that could be passed down to your children and their likelihood of getting cancer.

SAMPLE TYPES

Peripheral blood

Oral swabs

HERIGUARD®

Targets 208 genes associated with 37 types of inherited cancers  

Heriguard® comprehensively tests germline genetic alterations to thoroughly reveal hereditary risks in multiple cancer types (see table below). It could be used to screen high-risk populations for different cancer types, guide early diagnosis and prompt intervention before cancer occurs – all of which greatly improve treatment outcomes.  

WHO IS IT FOR
  • Individuals with one or more immediate family member with a single or multiple primary malignant tumors 
  • Individuals with a family history of early onset of tumors, before the age of 50 
  • Individuals with rare malignant tumors, i.e. breast cancer in men 
  • Individuals with precancerous lesions or symptoms, i.e. inflammatory polyps, atypical breast hyperplasia  
  • Individuals who would like to know their hereditary risk of for developing cancer 

Hereditary Cancer Types

Bladder cancer   Breast cancer  Cholangiocarcinoma 
Colorectal cancer  Endometrial cancer*  Esophageal cancer 
Gastric cancer  Intestine cancer  Kidney cancer 
Leukemia  Liver cancer  Lung cancer 
Ovary cancer*  Testicular cancer#  Thyroid cancer  
Pancreatic cancer  Prostate cancer#   
*, female only cancers; #, male only cancers. 
Contact us today to learn more about Heriguard®

HERIGUARD®MMR

Identifies inherited predisposition to gastrointestinal (GI) cancer 

Heriguard® MMR reports germline genetic alterations in 24 genes, including mismatch repair (MMR) genes – a class of genes responsible for correcting mismatch errors that arise during DNA replication. The panel evaluates the hereditary risk of GI cancer while providing genetic evidence for diagnosing a series of hereditary cancer syndromes including hereditary non-polyposis colon cancer (HNPCC, also known as Lynch syndrome), MUTYH-associated polyposis, hereditary pancreatic cancer and hereditary gastric cancer among others.

WHO IS IT FOR
  • Individuals with 10+ adenomatous polyps or 2+ hamartomatous polyps 
  • Individuals with one or more family members that have familial adenomatous polyposis (FAP) 
  • Individuals with one or more family members that have colorectal or endometrial cancer before the age of 50 
  • Individuals with two or more family members that has GI cancers at any age 
  • Individuals with family members diagnosed with tumor susceptibility syndrome or related tumors 

HERIGUARD®BRCA

A comprehensive test for detecting germline alterations in BRCA1/2 genes 

Heriguard® BRCA detects germline single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), and large  genomic rearrangements (LGR) of BRCA1/BRCA2 genesBRCA1/BRCA2 deleterious germline mutations increase the chance of developing cancers in breast, ovary, fallopian tubes, pancreas and prostate with high penetrance. By gaining early awareness of mutations, it could effectively prevent the occurrence of cancer or achieve early diagnosis/treatment through routine screening.

WHO IS IT FOR
  • Individuals with a family history of BRCA1/2 mutations
  • Individuals with one or more family members with diagnosed with breast cancer diagnosed before age 50, two or more family members with breast cancer at any age, one or more family members with early onset breast cancer diagnosed before age 45 or triple negative breast cancer diagnosed before age 60, or one or more family members with male breast cancer 
  • Individuals with one or more family members with that haveovarian cancer 
  • Individuals with two or more family members with  that have prostate or pancreatic cancer 
  • Individuals with two or more family members with that haveBRCA-associated cancers  

LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.

Learn more about our products and services or contact us today to discuss how we can partner together.

Contact Us